How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Active Tuberculosis Treatment Market
- By Treatment Regimen: First-line Anti-TB Drugs, Second-line Anti-TB Drugs, Short-course Chemotherapy, Directly Observed Therapy (DOT), Combination Therapy
- By Drug Class: Isoniazid, Rifampicin, Ethambutol, Pyrazinamide, Fluoroquinolones, Injectable Aminoglycosides
- By Drug Resistance Profile: Drug-Susceptible TB, Multidrug-Resistant TB (MDR-TB), Extensively Drug-Resistant TB (XDR-TB), Rifampicin-Resistant TB (RR-TB)
- By Patient Type: New TB Patients, Previously Treated TB Patients, HIV Co-infected TB Patients, Pediatric TB Patients, Latent TB Infection
- By Treatment Setting: Inpatient Treatment, Outpatient Treatment, Community-based Treatment, Directly Observed Therapy (DOT)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - First-line Anti-TB Drugs leads By Treatment Regimen at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Active Tuberculosis Treatment Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Regimen 5
Drug Class 6
Drug Resistance Profile 4
Patient Type 5
Treatment Setting 4
Companies profiled
Johnson & Johnson
Mylan N.V. (Viatris)
Sanofi
Cipla Limited
Lupin Limited
Dr. Reddy's Laboratories
Novartis AG
Zydus Cadila
GlaxoSmithKline (GSK)
Bharat Biotech
Aurobindo Pharma
Sun Pharmaceutical Industries
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Mylan N.V. (Viatris)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Sanofi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Cipla Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Lupin Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Dr. Reddy's Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Novartis AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Zydus Cadila
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →GlaxoSmithKline (GSK)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bharat Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Aurobindo Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sun Pharmaceutical Industries
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →AbbVie
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Pfizer
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Otsuka Pharmaceutical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,287M by 2033 · 7.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- First-line Anti-TB Drugs47.9
- Second-line Anti-TB Drugs11.4
- Short-course Chemotherapy7.9
- Directly Observed Therapy (DOT)15.4
- Combination Therapy17.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$787.6M → $1,567M · 9.0%
Europe$549.0M → $903.5M · 6.4%
Asia Pacific$501.2M → $848.3M · 6.8%
Latin America$310.3M → $586.5M · 8.3%
Middle East and Africa$238.7M → $401.3M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.552026
7.572027
7.582028
7.582029
7.602030
7.622031
7.632032
7.632033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson18.8
- Mylan N.V. (Viatris)13.7
- Sanofi10.6
- Cipla Limited11.8
- Lupin Limited9.0
- Dr. Reddy's Laboratories8.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Regimen26.3%
Drug Class14.0%
Drug Resistance Profile19.4%
Patient Type22.1%
Treatment Setting18.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.4
- Europe21.0
- Asia Pacific19.7
- Latin America13.6
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 98 | 86 | 87 | 85 | 80 | 95 | 89 |
| Mylan N.V. (Viatris) | 89 | 91 | 87 | 72 | 72 | 69 | 80 |
| Sanofi | 68 | 85 | 72 | 79 | 72 | 68 | 74 |
| Cipla Limited | 78 | 77 | 70 | 71 | 62 | 78 | 73 |
| Lupin Limited | 56 | 71 | 77 | 59 | 60 | 59 | 64 |
| Dr. Reddy's Laboratories | 49 | 68 | 70 | 66 | 57 | 70 | 63 |
| Novartis AG | 41 | 47 | 63 | 45 | 43 | 56 | 49 |
| Zydus Cadila | 35 | 59 | 46 | 52 | 45 | 43 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson
- Mylan N.V. (Viatris)
- Sanofi
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson | ✓ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Mylan N.V. (Viatris) | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Sanofi | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Cipla Limited | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Lupin Limited | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Dr. Reddy's Laboratories | ◐ | ◐ | ◐ | − | − | ◐ |
| Novartis AG | − | − | ◐ | ◐ | − | ◐ |
| Zydus Cadila | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Johnson & Johnson89
2Mylan N.V. (Viatris)80
3Sanofi74
4Cipla Limited73
5Lupin Limited64
6Dr. Reddy's Laboratories63
7Novartis AG49
8Zydus Cadila47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Johnson & JohnsonMylan N.V. (Viatris)
Challenger2
Strong scale, closing on the leaders.
SanofiCipla Limited
Contender2
Focused players with pockets of strength.
Lupin LimitedDr. Reddy's Laboratories
Niche2
Specialists in a single segment or region.
Novartis AGZydus Cadila
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Regimen in North America, then scale across Active Tuberculosis Treatment Market — a $456M beachhead inside a $7.18B market.
Beachhead (SOM)$456Mobtainable near-term
Serviceable (SAM)$2.74Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
First-line Anti-TB Drugs
Best fit — highest urgency & budget in Treatment Regimen.
Economic buyer75 fit
Second-line Anti-TB Drugs
Strong fit — clear ROI and a fast path to value.
End user65 fit
Short-course Chemotherapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Regimen in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Resistance Profile
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Regimen leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Active Tuberculosis Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified22%
Evaluation15%
Closed-won7%
$11.5KCAC
$39KLTV
3.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Active Tuberculosis Treatment Market is a high-growth opportunity — $9.60B by 2033, compounding at 10.6%.
TAM · 2025$4.28Btoday
TAM · 2033$9.60Bforecast
CAGR10.6%2027–2033
Cumulative$59.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.60BTotal addressable market
SAM$3.39BServiceable available market
SOM$727MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.6% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Regimen.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Regimen moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.60BLarge & growingTAM by 2033 at 10.6% CAGR
$3.39BServiceable nowreachable with today’s model
$727MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.49BBear6.9% CAGR
$9.60BBase10.6% CAGR
$12.3BBull14.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Active Tuberculosis Treatment Market — a $10.7B market by 2033. Plan: grow share from 9.1% to 15.1%.
Market size · 2033$10.7Btotal addressable
Market CAGR11.5%2027–2033
Target share15.1%from 9.1% today
Revenue ambition$1.62Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.1% | 15.1% | On track |
| Revenue | $1.06B | $1.62B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 31.0% | 40.1% | At risk |
| Customer retention | 88.2% | 94.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Regimen
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Regimen share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $181M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Regimen leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Active Tuberculosis Treatment Market conversation — a $7.71B market you can size, segment and defend in minutes.
Market size · 2033$7.71Btotal opportunity
Growth11.0%CAGR to 2033
Addressable buyers1,560+accounts in scope
Typical ROI4.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Regimen
Goal Grow share in Treatment Regimen
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.5×return on cost, year one
< 3 mopayback period
$77K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Johnson & JohnsonMylan N.V. (Viatris)SanofiCipla LimitedLupin LimitedDr. Reddy's LaboratoriesNovartis AGZydus Cadila+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Active Tuberculosis Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Active Tuberculosis Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Hospice Care Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportMental Health Care Software and Services Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMental Health EHR Software Market
Mental Health EHR Software Market is valued at USD 3.24 Billion in 2025 and is expected to reac…
$3.2B market · 2025 base year
View reportMental Health Software and Devices Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportMedical Coding and Billing Services Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportMedical Coding Service Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportMedical Billing Outsourcing Services Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportMedical Billing Service Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportMedical Billing Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportMedical Appointment Scheduling Software Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportActive Safety Needle Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportLiquid Encapsulation Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.